In vitro and in vivo clinical and experimental data have suggested that leukotrienes play a key role in infl ammatory reactions of the skin. Antileukotriene drugs, ie, leukotriene receptor antagonists and synthesis inhibitors, are a class of anti-infl ammatory drugs that have shown clinical effi cacy in the management of asthma and in rhinitis with asthma. We searched MEDLINE database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective in chronic urticaria associated with aspirin (ASA) or food additive hypersensitivity or with autoreactivity to intradermal serum injection (ASST) when taken with an antihistamine but not in mild or moderate chronic idiopathic urticaria [urticaria without any possible secondary causes (ie, food additive or ASA and other NSAID hypersensitivity, or ASST)]. Evidence for the effectiveness of zafi rlukast and the 5-lipoxygenase inhibitor, zileuton, in chronic urticaria is mainly anecdotal. In addition, there is anecdotal evidence of effectiveness of antileukotrienes in primary cold urticaria, delayed pressure urticaria and dermographism. No evidence exists for other physical urticarias, including cholinergic, solar and aquagenic urticarias, vibratory angioedema, and exercise-induced anaphylaxis. Keywords: chronic idiopathic urticaria, leukotriene receptor antagonists, montelukast, zafi rlukast, antihistamine Urticaria is a common disorder of the skin, affecting between one in four and one in six people, sometimes throughout their lives. Urticarial episodes of up to 6 weeks' duration are classifi ed as acute, whereas those lasting longer are considered chronic. The clinical characteristic of chronic urticaria (CU) are repeated occurrences of short-lived cutaneous wheals accompanied by redness and itching exceeding 6 weeks. The individual wheals last less than 24 hours, with the exceptions of delayed pressure urticaria and urticarial vasculitis, which persist for 24 to 72 hours. Wheals are lesions ranging from a few millimeters to several centimeters in diameter. The itch of urticaria is the hallmark symptom, and it is usually worse in the evening or nighttime. CU typically follows this diurnal pattern. Angioedema (AE) accompanies 40% to 50% of the cases of chronic urticaria and 10% of the patients experience only AE without hives. [1] [2] [3] In these patients the treatments have focused on symptom control.
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The most popular theory to explain the development of CU is referred to as the autoimmune hypothesis. This notion had its origins in 1924, when Lewis and Grant improved the technique of experimentally creating histamine wheals initially described by Eppinger in 1913. 4 The suggestion that chronic idiopathic urticaria (CIU) may have an autoimmune basis came from the recognition that thyroid auto-antibodies and thyroid dysfunction were observed more commonly in patients with CIU. 4 The suggestion that a serologic factor is responsible for the pathogenesis of CIU has been a dominant theme in the literature for more than 20 years. In 1986, a serologic mediator called HRF was identifi ed in patients with CU using an in vivo skin test called the autologous serum skin test (ASST). 5 We demonstrated that both aspirin (ASA) and food additives determine a signifi cant increase in urinary leukotriene 4 (LTE 4 ) levels, after oral specifi c challenge in patients with CU and hypersensitivity to ASA or food additives. The urinary LTE 4 levels were compared between patients with CU and hypersensitivity to ASA or food additives, patients with CU but tolerating both ASA and food additives, and healthy subjects. No difference was found at baseline between the three groups. After a specifi c challenge with ASA and food additives, the urinary excretion levels of LTE 4 were significantly higher in patients affected by CU and hypersensitivity to ASA or food additives than in patients with CU but without hypersensitivity to ASA or food additives and in healthy subjects.
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Therapy of urticaria
The management of CU remains a challenge for both clinicians and patients. Primary recommendations for the management of CU include general measures such as avoidance of any aggravating stimuli, topical antipruritic emollients, reassurance and education, and specifi c pharmacotherapy, of which the newer selective H1-antihistamines are the preferred intervention.
1 However, the prior generation "sedating" antihistamines remain useful, effi cacious fi rst-line agents for many patients.
Some of these nonselective antihistamines have other useful receptor properties that may extend additional effi cacy in certain cases. Such agents include doxepin, cyproheptadine, and ketotifen. [8] [9] [10] The H2-antihistamines are also used in clinical practice, most often as add-on therapy, but these agents generally offer modest incremental effi cacy. 11 In addition to combining multiple antihistamines in such a way, higher doses of antihistamines are widely recommended or prescribed; 12 however, the evidence supporting this practice is minimal. 13 Oral corticosteroids almost always control urticaria and are undoubtedly the most versatile and useful second-line therapy. However, the incidence of side-effects is substantial if the dose, the duration of use, or both, are too great.
14 Other second-line therapies include sulphasalazine 15 and thyroxine. 16 While third-line, immunosuppressive therapies for severe CU are now accepted practice, there is still the problem of knowing which patients have autoimmune urticaria and are therefore most likely to respond, even if there is some evidence for the therapeutic effect of immunosuppression therapy in patients without autoimmune urticaria. 17 Newer biologic and nonbiologic immunomodulatory agents, approved for other indications and in clinical development, provide potential options for this often severe CU.
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Urticaria treatment with antileukotrienes
The efficacy and, primarily, safety of the leukotriene modifi ers have placed these agents at the top of the list of alternative agents, and future practice may place them alongside antihistamines as fi rst-line therapy. 19 We searched MEDLINE database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Even though treatment with antileukotrienes in urticaria has not been recommended by manufacturers of the drugs, we found numerous anecdotal and open-series reports and some placebo-controlled studies on the treatment of urticaria with cysteinyl-leukotriene antagonists. The studies were evaluated using the parameters of Shekelle (Tables 1, 2) . 20 
Rationale of the treatment with antileukotrienes
Injected leukotriene D4 is more potent than histamine in causing a wheal and fl are. 21 Serum from patients with CIU with positive ASST or negative ASST, since patients cannot have both idiopathic and autoimmune disease, is capable of releasing leukotrienes, in addition to other mediators. 22 Leukotriene-mediated urtication is not blocked by other agents. 23 
Anecdotal series and open studies
Anecdotal studies suggested therapeutic effects for antileukotrienes in the treatment of urticaria exacerbations induced by ASA 24 and other nonsteroidal anti-infl ammatory drugs (NSAIDs) in patients with CIU, 25 
chronic autoimmune
Leukotriene receptor antagonists for chronic urticaria urticaria, 26 acquired cold urticaria, 27, 28 delayed-pressure urticaria (DPU), 29 and intractable CIU. 30 A single negative study reported a pranlukast-evoked urticaria in patients affected by ASA-induced urticaria. 31 However, this molecule is not marketed in Europe and in US (Table 3) .
Other open studies, with more patients, suggested a benefi cial effect for antileukotrienes in the treatment of DPU, 32 steroid-dependent urticaria 33, 34 chronic idiopathic urticaria, 35, 36 and dermographism. 35 Patients with allergic urticaria showed less benefi t. 35 Nettis et al treated patients affected by chronic idiopathic urticaria with montelukast or fexofenadine. They demonstrated that montelukast had a better therapeutic effects compared with fexofenadine. The majority of the patients presented a positive ASST and, after therapy with montelukast, were unreactive to autologous serum. 37 A case report suggested a benefi cial effect for antileukotrienes in the treatment of urticaria exacerbation induced by a COX-2 selective inhibitors. 38 Another study demonstrated in 22/25 patients the effect of antileukotrienes in the treatment of urticaria exacerbation induced by ASA or NSAIDs. 39 Finally, a comparison between montelukast and cetirizine demonstrated that cetirizine is better than montelukast in monotherapy. 40 
Controlled studies
A double-blind, placebo-controlled study demonstrated a better therapeutic effect of montelukast vs cetirizine and placebo in patients with ASA and ⁄or food additive-induced urticaria. 41 Perez et al demonstrated that in individuals with histories of recurrent episodes of urticaria and⁄or angioedema after the administration of different NSAIDs, pretreatment with montelukast before a single-blind oral challenge with NSAIDs, completely or partially prevented the reaction in most of those patients. 42 In a double-blind, placebo-controlled trial comparing cetirizine plus zafi rlukast vs cetirizine plus placebo in patients affected by CU refractory to H1-antagonist monotherapy, Bagenstose et al demonstrated that only patients with autoreactive (positive ASST) CU might benefi t from the addition of the leukotriene receptor antagonist zafi rlukast to their treatment regimen. 43 A randomized, single-blind, placebo-controlled, crossover study with montelukast vs placebo, using a nonsedating H1-antihistamine when needed, demonstrated that montelukast might be an effective and safe therapeutic agent in the treatment of patients with refractory chronic idiopathic urticaria, including patients with intolerance to NSAIDs and positivity to ASST. 44 Reimers et al in a double-blind, placebo-controlled, crossover study, treated with zafi rlukast a heterogeneous population of patients with CU. In comparison with placebo, treatment with zafi rlukast resulted in no signifi cant positive effect for any of the effi cacy measures, but it may be relevant that a high proportion of patients had dermographism. 45 Nettis et al reported on another randomized, doubleblind, placebo-controlled study conducted on patients with a diagnosis of mild CU, randomized to receive once daily: (a) oral desloratadine plus placebo; (b) desloratadine plus montelukast; or (c) oral placebo alone. In this study, the combination of desloratadine plus montelukast was effective in the treatment of CU. 46 Di Lorenzo et al treated 160 patients affected by chronic idiopathic urticaria with montelukast alone or in combination with a nonsedating antihistamine (desloratadine), or only with nonsedating antihistamine, or with matched placebo. In this study, we evaluated only patients affected by moderate chronic idiopathic urticaria. This is an important difference compared with some of the previous reports, in which patients were selected without precise characteristics. 33, 34, 46 In patients with moderate chronic idiopathic urticaria, the role of leukotrienes is probably rather insignifi cant. 6, 43 In this study, montelukast alone was less effective than the combination with nonsedating antihistamine and appeared not to be useful in controlling the symptoms of urticaria compared with nonsedating antihistamine alone. Therefore, the expected synergistic interaction between antileukotrienes and antihistamines was not confi rmed in mild chronic idiopathic urticaria. 47 This result is in accordance with another noncontrolled study 40 (Table 4) .
Conclusions
Leukotriene receptor antagonists are currently the beststudied group of drugs after the antihistamines, in the therapy of CU. However, the leukotriene receptor antagonists aren't alternative agents to antihistamines. The excellent safety, absence of required monitoring in the case of montelukast and zafi rlukast, and wide availability make leukotriene receptor antagonists the preferred supplementary agents to try with antihistamines. Although one study suggested persistent drug-free remission, 44 most experience argues against such a disease-modifying effect. Leukotriene receptor antagonists appear to be useful as both monotherapy and add-on therapy but are not likely to displace antihistamines from their role as fi rst-line therapy.
In our review, leukotriene receptor antagonists may provide improvement in patients with food additive hypersensitivity or ASA and other NSAID-exacerbated CIU 24, 25, 31, 38, 39, 41, 42 and in patients with positive ASST results. 26, 37, 44 In other words, in the type of chronic urticaria without any associated cause, very idiopathic urticaria, the use of leukotriene receptor antagonists demonstrates lack of advantage if administered both in monotherapy and combined with antihistamines.
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